Vertex Pharma Is One of Our Favorite Biotechs

Image: Vertex Pharma has performed quite well since the beginning of 2023.

By Brian Nelson, CFA

Vertex Pharma (VRTX) reported mixed fourth quarter results February 10 with revenue outpacing the consensus forecast, but non-GAAP earnings per share coming in a bit light relative to expectations. In the quarter, product revenue increased 16% thanks to the continued performance of TRIKAFTA/KAFTRIO. In the U.S., net product revenue increased 17%, while net product revenue outside the U.S. increased 14%. GAAP and non-GAAP net income in the quarter came in at $913 million and $1.0 billion, respectively, lower than the $969 million and $1.1 billion, respectively, for the fourth quarter of 2023.

Management had the following to say about the quarter in the press release:

2024 marked a year of tremendous growth for Vertex and we anticipate 2025 will be another important year with the landmark JOURNAVX approval and launch for moderate-to-severe acute pain; the launch of our fifth CF medicine, ALYFTREK; the continuing global launch of CASGEVY; and multiple ongoing pivotal trials. We are excited to drive diversification of the revenue base, disease areas of focus, R&D pipeline, and geographies to continue to deliver long-term value to both patients and shareholders.

Looking to 2025, Vertex expects total revenue of $11.75-$12 billion, which includes expectations for continued growth in its cystic fibrosis portfolio, “including the U.S. launch of ALYFTREK, as well as continued uptake of CASGEVY in multiple regions; and early contributions from the launch of JOURNAVX.” Cash and total marketable securities as of the end of last year were $11.2 billion, compared to $13.7 billion at the end of 2023 due to the cash consideration paid to acquire Alpine and share buybacks. Vertex had no traditional debt. We continue to like Vertex Pharma as a holding in the Best Ideas Newsletter portfolio.

—–